Study for ovarian cancer showing resistance to platinum chemotherapy
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at ovarian cancer patients who are planned to receive platinum-based chemotherapy and who may have resistance issues. It may help doctors learn better ways to treat ovarian cancer when platinum drugs don’t work well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have epithelial ovarian cancer diagnosed for the first time (all stages)
- Curative surgery has not started yet (except you may have already had chemotherapy before surgery)
- Your treatment plan includes platinum-based chemotherapy
- You are covered by the French social security system
- You can sign consent before any study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
This study looks at genetic and other factors that may explain why some people with ovarian cancer respond well to platinum-based chemotherapy for many years, while others do not respond at all. The goal is to better understand these differences to improve future treatments.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This study looks at certain “DNA repair traits” (called homologous recombination phenotype) in people with epithelial ovarian cancer. Results may help researchers better understand who responds to platinum chemotherapy, which is commonly used for this cancer.
This study is looking for new ways to treat ovarian cancer that has become resistant to current therapies. By joining, you may help researchers develop better treatment options for women like you.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.